At a glance
ClinicalIndex Comparison RecordN/ACompleted· 83 enrolled
Drug / intervention
Molecular breast imagingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing
In Brief
A clinical study evaluating Molecular breast imaging for Breast Cancer. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The primary objective of this work is to determine if half-dose Molecular Breast Imaging (MBI) performed with 4 mCi Tc-99m sestamibi with or without Wide Beam Reconstruction applied can achieve image quality and diagnostic accuracy non-inferior to that of standard MBI performed with 8 millicurie (mCi) Tc-99m sestamibi.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsFriends for an Earlier Breast Cancer Test
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionMay 2016
TodayJul 2026
First PostedJul 31, 2012
Enrollment StartJul 1, 2012
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.9 years ago
Interventions
Molecular breast imagingother
Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)